Johnson & Johnson | Vision in the news
Leading eye health innovation
Tamtam found 19 recent articles about Johnson & Johnson | Vision.
- Johnson & Johnson to Highlight IOL Contrast Data, Smartload Delivery Technology at AAO
Johnson & Johnson will highlight new IOL contrast data, launch the Smartload Delivery Technology, and present enhancements to its surgical systems at the 2026 American Academy of Ophthalmology annual meeting.
- Johnson & Johnson's Innovative Medicines Momentum Offsets MedTech Headwinds, RBC Capital Markets Says
RBC Capital Markets indicates Johnson & Johnson's Innovative Medicines are offsetting MedTech challenges.
- Johnson & Johnson, AOA Reveal Menopause Eye Health Gap
Johnson & Johnson and the American Optometric Association released a study revealing that most menopausal women fail to recognize vision changes as a symptom of menopause and do not seek appropriate optometric care.
- Permits OK’d for J&J North Jacksonville distribution center
Johnson & Johnson's new North Jacksonville distribution center, part of a $1 billion investment, is progressing with permits secured and will enhance its Vision operations for ACUVUE contact lenses.
- Johnson & Johnson survey finds women not connecting menopause to eye health changes
Johnson & Johnson's survey found many women don't link eye changes to menopause, prompting an awareness campaign with Naomi Watts to encourage eye health discussions.
- Johnson & Johnson Survey Finds Awareness Gap Around Eye Changes During Menopause
A Johnson & Johnson survey found a significant awareness gap regarding eye changes during menopause, as many women experience symptoms but do not discuss them with eye care professionals.
- Johnson & Johnson Data Highlight Moisture Retention Differences Among Daily Disposable Contact Lenses
Johnson & Johnson presented new research on contact lens moisture retention, presbyopia, and patient satisfaction with Acuvue lenses at a recent optometry meeting.
- Johnson & Johnson Acuvue Oasys lenses demonstrate favorable moisture retention
Johnson & Johnson's Acuvue Oasys lenses show superior moisture retention, while new data highlights patient and optometrist perspectives on presbyopia and the positive user experience with Acuvue Vita reusable lenses.
- Rx Rundown: Lilly, Bristol Myers Squibb, Johnson & Johnson and more
This document summarizes recent news in the pharmaceutical and healthcare industry, covering deals, FDA approvals, funding, layoffs, and other industry updates from various companies including Eli Lilly, Bristol Myers Squibb, and Johnson & Johnson.
- CAR-T manufacturing & delivery for multiple myeloma patients
Johnson & Johnson's Jessica Torfs manages the complex global supply chain for CAR-T cell therapy for multiple myeloma patients, ensuring personalized treatment delivery from cell collection to infusion.
- 2026 2H Healthcare Dividend Roundup: Johnson & Johnson Outshines AbbVie (NYSE:ABBV)
Johnson & Johnson maintains a higher valuation than AbbVie due to its strong financial health, conservative balance sheet, and effective capital allocation strategies.
- Johnson & Johnson: What the Street’s Reaction to OTTAVA Actually Reveals About the Stock
Johnson & Johnson's new surgical robot OTTAVA received FDA approval amid a slowdown in its MedTech segment, with significant financial contributions not expected until the next decade.
- What Johnson & Johnson (JNJ)'s Bipolar I Mania Data for CAPLYTA Means For Shareholders
Johnson & Johnson released positive Phase 3 results for CAPLYTA (lumateperone) in treating bipolar I mania, potentially expanding its market and reinforcing the company's strategy towards innovative medicines.
- Johnson & Johnson Sees Path to Double-Digit Growth Despite 2026 Patent Cliff
Johnson & Johnson expects double-digit growth in the coming years, driven by its pharmaceutical pipeline and MedTech portfolio, despite a significant patent cliff in 2026.
- Johnson & Johnson Exits LAA Closure Market, Sells Tech to Jaguar
Johnson & Johnson is selling its Laminar left atrial appendage closure technology to Jaguar LAA after suspending a pivotal trial due to device issues.
- Newly formed Jaguar acquires AFib device assets from J&J
Jaguar LAA acquired Johnson & Johnson's Laminar program assets, a catheter-based device for left atrial appendage closure.
- Johnson & Johnson Targets Double-Digit Growth as STELARA Faces Biosimilar Competition
Johnson & Johnson forecasts significant revenue and EPS growth, targeting double-digit growth by the decade's end despite biosimilar competition, and will detail its strategy in December.
- Johnson & Johnson Tags Jacqueline Henderson as Company Group Chair, Vision
Jacqueline Henderson has been appointed Company Group Chair, Vision, at Johnson & Johnson, overseeing global Vision Care and Surgical Vision segments.
- Is Johnson & Johnson (JNJ) Resetting Its Device Business With Two Fresh Moves?
Johnson & Johnson is adjusting its medical device business through new contact lens approval and divestment of a heart device program.
Articles collected by Tamtam and kept when they are about the company, newest first. Each links to its source.
Selling to companies like Johnson & Johnson | Vision?
Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.
Find similar companies